NASDAQ:CERSCerus Stock Price, Forecast & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CERS stock has increased by 23.9% and is now trading at $5.90. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerus.

Cerus is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) issued its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.00. The biotechnology company earned $18.61 million during the quarter, compared to analyst estimates of $17.60 million. Cerus had a negative net margin of 90.97% and a negative return on equity of 93.16%. View Cerus' earnings history.

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $111.9 million.

3 equities research analysts have issued 1 year target prices for Cerus' stock. Their forecasts range from $6.50 to $8.00. On average, they expect Cerus' stock price to reach $7.17 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View analysts' price targets for Cerus.

Media headlines about CERS stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cerus earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutCerus.

Some companies that are related to Cerus include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Anika Therapeutics (ANIK) and Antares Pharma (ATRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Opko Health (OPK), Grayscale Bitcoin Trust (Btc) (GBTC), ACADIA Pharmaceuticals (ACAD), Aduro BioTech (ADRO) and Celldex Therapeutics (CLDX).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.63%), Primecap Management Co. CA (6.83%), Nikko Asset Management Americas Inc. (6.53%), Nikko Asset Management Americas Inc. (6.53%), Sumitomo Mitsui Trust Holdings Inc. (6.52%) and State Street Corp (2.47%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman. View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Two Sigma Investments LP, Millrace Asset Group Inc., Primecap Management Co. CA, Morgan Stanley, Morgan Stanley, Baird Financial Group Inc., and Two Sigma Advisers LP. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman. View insider buying and selling activity for Cerus.

CERS stock was bought by a variety of institutional investors in the last quarter, including Silvercrest Asset Management Group LLC, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Sumitomo Mitsui Trust Holdings Inc., Paradigm Capital Management Inc. NY, First Midwest Bank Trust Division, and Geode Capital Management LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman. View insider buying and selling activity for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $5.90.

Cerus has a market capitalization of $967.54 million and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]